These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987. Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237 [TBL] [Abstract][Full Text] [Related]
23. Survey of Bacteroides fragilis susceptibility patterns in France. Breuil J; Burnat C; Patey O; Dublanchet A J Antimicrob Chemother; 1989 Jul; 24(1):69-75. PubMed ID: 2777729 [TBL] [Abstract][Full Text] [Related]
24. Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital. Yim J; Lee Y; Kim M; Seo YH; Kim WH; Yong D; Jeong SH; Lee K; Chong Y Ann Lab Med; 2015 Jan; 35(1):94-8. PubMed ID: 25553287 [TBL] [Abstract][Full Text] [Related]
25. Antibiotic sensitivity of the Bacteroides fragilis group in Europe. European Study Group. Phillips I; King A; Nord CE; Hoffstedt B Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):292-304. PubMed ID: 1396748 [TBL] [Abstract][Full Text] [Related]
26. [Evolution of the sensitivity of Bacteroides group fragilis at the Sevilla University Hospital (1983-1987)]. Borobio MV; Domínguez MC; Pallares JA; Perea EJ Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):214-8. PubMed ID: 1863620 [TBL] [Abstract][Full Text] [Related]
27. Susceptibility of cefotetan and Sch 34343 to beta-lactamases produced by strains of Bacteroides that hydrolyse cefoxitin or imipenem. Andrew JH; Greenwood D J Antimicrob Chemother; 1987 May; 19(5):591-5. PubMed ID: 3497146 [TBL] [Abstract][Full Text] [Related]
28. Susceptibility of the Bacteroides fragilis group in the United States in 1981. Tally FP; Cuchural GJ; Jacobus NV; Gorbach SL; Aldridge KE; Cleary TJ; Finegold SM; Hill GB; Iannini PB; McCloskey RV; O'Keefe JP; Pierson CL Antimicrob Agents Chemother; 1983 Apr; 23(4):536-40. PubMed ID: 6859833 [TBL] [Abstract][Full Text] [Related]
29. Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group. Cuchural GJ; Tally FP; Jacobus NV; Cleary T; Finegold SM; Hill G; Iannini P; O'Keefe JP; Pierson C Antimicrob Agents Chemother; 1990 Mar; 34(3):479-80. PubMed ID: 2334161 [TBL] [Abstract][Full Text] [Related]
30. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States. Aldridge KE; Gelfand M; Reller LB; Ayers LW; Pierson CL; Schoenknecht F; Tilton RC; Wilkins J; Henderberg A; Schiro DD Diagn Microbiol Infect Dis; 1994 Apr; 18(4):235-41. PubMed ID: 7924220 [TBL] [Abstract][Full Text] [Related]
31. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group. Bourgault AM; Lamothe F J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324 [TBL] [Abstract][Full Text] [Related]
32. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents. Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111 [TBL] [Abstract][Full Text] [Related]
33. Occurrence of metronidazole and imipenem resistance among Bacteroides fragilis group clinical isolates in Hungary. Nagy E; Sóki J; Urban E; Szoke I; Fodor E; Edwards R Acta Biol Hung; 2001; 52(2-3):271-80. PubMed ID: 11426861 [TBL] [Abstract][Full Text] [Related]
34. Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992. Dubreuil L; Breuil J; Dublanchet A; Sedallian A Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1094-9. PubMed ID: 1295764 [TBL] [Abstract][Full Text] [Related]
35. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns. Aldridge KE; Ashcraft D; O'Brien M; Sanders CV Antimicrob Agents Chemother; 2003 Jan; 47(1):148-53. PubMed ID: 12499183 [TBL] [Abstract][Full Text] [Related]
36. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents. Aldridge KE; Henderberg A; Sanders CV J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826 [TBL] [Abstract][Full Text] [Related]
37. beta-Lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents. Jacobs MR; Spangler SK; Appelbaum PC Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1081-93. PubMed ID: 1295763 [TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982. Cuchural GJ; Tally FP; Jacobus NV; Gorbach SL; Aldridge K; Cleary T; Finegold SM; Hill G; Iannini P; O'Keefe JP Antimicrob Agents Chemother; 1984 Aug; 26(2):145-8. PubMed ID: 6486758 [TBL] [Abstract][Full Text] [Related]
39. In vitro susceptibility vs. in vivo efficacy of various antimicrobial agents against the Bacteroides fragilis group. Brook I Rev Infect Dis; 1991; 13(6):1170-80. PubMed ID: 1775850 [TBL] [Abstract][Full Text] [Related]
40. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]